Virtual Presentation

The Role of Allogeneic Hematopoietic Cell Transplantation in AML

Source: Navigating the Therapeutic Pathways for AML and MDS

The Role of Allogeneic Hematopoietic Cell Transplantation in AML

Faculty:

Frederick R. Appelbaum, MD

CREDIT INFORMATION

Release Date: February 17, 2010

Expiration Date: February 16, 2011

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the use of allogeneic transplantation in patients with AML who fail induction therapy
Cite cytogenetic abnormalities that affect outcomes in patients with AML receiving allogeneic transplantation
Understand outcomes between matched related donor, matched unrelated donor, and cord blood in allogeneic transplantation of patients with AML
Compare outcomes of allogeneic transplantation and chemotherapy in older patients with AML

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.